Celltrans, Inc.
🇺🇸United States
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
- Conditions
- Type 1 Diabetes Mellitus
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- CellTrans Inc.
- Registration Number
- NCT03791567
- Locations
- 🇺🇸
University of Illinois at Chicago Medical Center, Chicago, Illinois, United States
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
Phase 3
Active, not recruiting
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Biological: Islets of Langerhans transplantation
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- CellTrans Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00679042
- Locations
- 🇺🇸
University of Illinois at Chicago Medical Center, Chicago, Illinois, United States
News
Lantidra Approved for Brittle Type 1 Diabetes, Offering New Hope for Insulin Independence
Lantidra, derived from deceased donor pancreas, is the first FDA-approved therapy for brittle type 1 diabetes, addressing severe low blood sugar episodes.